Pharmaceutical Composition for Preventing or Treating Cancer Comprising TUT4/7 Expression Modulator

EPO published Patent Application EP3904518A1 for a pharmaceutical composition comprising a TUT4/7 expression modulator for preventing or treating cancer, with applicants Seoul National University R&DB Foundation and Institute for Basic Science. The granted patent provides exclusive rights covering nucleic acid-based compositions targeting terminal uridylyltransferases TUT4 and TUT7 in cancer therapy.

Pharmaceutical companies and biotech researchers developing RNA uridylylation-targeted cancer therapeutics should evaluate freedom-to-operate and potential licensing needs. The patent's designated states cover all major European markets (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), creating IP risk across the EPC contracting states.